Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Company Overview

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases that affect skeletal muscle and other tissues. The company uses its FulcrumSeek drug-discovery platform to identify molecular targets and potential therapies for conditions in which the underlying biology is well characterized but treatment options remain limited.

Fulcrum’s lead product candidate is losmapimod, an investigational oral therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited muscle-wasting disorder. Losmapimod is designed to inhibit p38 alpha and p38 beta mitogen-activated protein kinases and reduce expression of DUX4, a gene believed to play a central role in FSHD. The company has also pursued programs in other genetic and rare diseases, including sickle cell disease, although its development pipeline may change as clinical and strategic priorities evolve.

Founded in 2016 and headquartered in Waltham, Massachusetts, Fulcrum conducts research and clinical development activities primarily through collaborations and studies involving patients and healthcare providers in the United States and other regions. The company is led by President and Chief Executive Officer Robert J. Gould, Ph.D., who is also a co-founder.

Key Stats

• Today's Range: $3.71 to $3.76
• 50-Day Range: $3.58 to $3.91
• 52-Week Range: $2.83 to $15.74
• Volume: 901,247 shs
• Average Volume: 1.63 million shs
• Market Capitalization: $283.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.20
• Consensus Rating: Reduce

Fulcrum Therapeutics Stock Analysis - MarketRank™

Fulcrum Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 690th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Fulcrum Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 7 hold ratings, and 4 sell ratings.

Upside Potential

Fulcrum Therapeutics has a consensus price target of $8.20, representing about 120.4% upside from its current price of $3.72.

Amount of Analyst Coverage

Fulcrum Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($0.60) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulcrum Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulcrum Therapeutics is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulcrum Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.17% of the float of Fulcrum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 5.87.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently increased by 2.55%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulcrum Therapeutics does not currently pay a dividend.

Dividend Growth

Fulcrum Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.43

News Sentiment

Fulcrum Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Fulcrum Therapeutics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fulcrum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.30% of the stock of Fulcrum Therapeutics is held by insiders.

Percentage Held by Institutions

89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FULC
• CIK: 1680581
• Web: www.fulcrumtx.com
• Phone: (617) 651-8851
• Fax: N/A
• Employees: 55
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Fulcrum Therapeutics: $8.20
• High Price Target: $24.00
• Low Price Target: $3.00
• Potential Upside/Downside: +120.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -25.38%
• Return on Assets: -24.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 31.35
• Quick Ratio: 31.35

Sales & Book Value

• Annual Sales: $80 million
• Price / Sales: 3.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.45 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 76,300,000
• Free Float: 70,727,000
• Market Cap: $283.84 million
• Optionable: Optionable
• Beta: 2.59